Locations:

Better, Faster, Stronger: Intensity-Modulated, Accelerated Partial Breast Radiation Therapy

Full treatment in five fractions

Dr.Murphy&EDGE_650x450

When Chirag Shah, MD, became a radiation oncologist in 2007, almost all breast cancer patients had one option: five to six weeks of daily, whole-breast/chest-wall radiation, regardless of surgical type (mastectomy or lumpectomy). A mere decade later, thanks to advances in the field in part refined at Cleveland Clinic Cancer Center, patients can choose among several options for radiotherapy, many of which are safer and shorter without compromising efficacy. Dr. Shah is directing Cleveland Clinic Cancer Center’s adoption of new techniques to significantly reduce the duration of radiation therapy treatments for appropriately selected patients, from three to four weeks to just five treatments.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Intensity-modulated, accelerated partial breast radiation therapy

Accelerated partial-breast irradiation (APBI) allows appropriately selected patients with early-stage breast cancer to complete adjuvant radiation in two weeks or less following breast-conserving surgery. To date, multiple randomized trials have demonstrated no difference in rates of recurrence or survival with APBI delivered using brachytherapy or external beam radiation techniques.

For patients with ductal carcinoma in situ (DCIS) ­and early-stage invasive breast cancer, APBI has been shown to be an alternative to standard whole-breast irradiation, allowing for a reduction in the duration of radiation therapy. The technique, by reducing the amount of normal, healthy breast tissue treated with radiation, may also reduce side effects of treatment and improve cosmetic outcomes. It is also considered a cardiac and pulmonary dose-sparing technique.

One method of delivering APBI is intensity-modulated radiation therapy (IMRT), a highly precise form of radiotherapy. Cleveland Clinic Cancer Center employs a team of highly trained specialists that utilize the Edge® (Varian Medical Systems Inc.) radiosurgical suite. The Edge is a state-of-the-art linear accelerator coupled with real-time motion management to ensure fast, precise delivery of treatment. The six-degree freedom couch, which accounts for motion in multiple directions, allows for accurate patient positioning while a CT scan attached to the machine allows accurate targeting of the area at risk.

”Combining active breathing control (ABC) with IMRT reduces cardiac dosing even further,” says Dr. Shah, Director of Clinical Research and Breast Radiation in the Department of Radiation Oncology. “We can usually line this up with an accuracy of within a few millimeters.”

Advertisement

IMRT is commonly used to treat prostate, head and neck and central nervous system cancers. Dr. Shah’s team is refining its use in breast cancer to deliver partial breast irradiation. IMRT can deliver higher doses with fewer side effects and reduced treatment toxicity, but it does require more planning than other traditional methods. “Still, we’ve submitted a study showing that our five-fraction treatment reduces costs for patients and health systems. Although it uses more advanced technology, it saves money because of fewer treatments, less time in treatment, less missed work and reduced overall expenses.”

With a variety of innovations and radiation technique trials available to patients, Dr. Shah is optimistic about the ability of breast radiation oncology to increase its impact on patient survival and quality of life. “In the short years I’ve been practicing, the field has exploded with better options for patients, and I believe we’ve only just begun.”

Photo Credit: Annie O’Neill

Advertisement

Related Articles

Patient and doctor
October 9, 2026/Cancer/News & Insight

First Radioligand Therapy Approved for Metastatic Hormone-Sensitive Prostate Cancer

Adding 177Lu-PSMA-617 to ADT plus an ARPI cut the risk of radiographic progression or mortality by 28%

Woman running
October 7, 2026/Cancer/Patient Support

Pilot Project Aids Cancer Survivors in Achieving Healthy Weight and Reducing Recurrent Risk

New program will help patients improve fitness and manage weight after cancer treatment

Dr Keith McCrae
October 6, 2026/Cancer/Benign Hematology

How is ITP Therapy Evolving?

Cleveland Clinic hematologist highlights new guidelines and treatment advances in immune thrombocytopenia

Bone metastasis
October 5, 2026/Cancer/Innovations

Digital Platform Cuts Bone Metastasis Treatment Decision Time

NIMBLE replaces weekly tumor board delays with same-day multidisciplinary recommendations

Prostate cancer
October 2, 2026/Cancer/Radiation Oncology

ArteraAI Prostate Biomarker Accurate Across Diverse Populations

Cleveland Clinic study provides validation for the test, which combines AI and pathological data to predict outcomes in postoperative patients

Prostate cancer illustration
October 1, 2026/Cancer/Radiation Oncology

PSMA PET Scan-Guided LDR Brachytherapy Can Control Localized Prostate Cancer Recurrence

Advanced imaging technology catches metastases much earlier, allowing treatment with fewer side effects

Throat cancer
September 30, 2026/Cancer/Radiation Oncology

Same Cure Rate, Less Radiation in HPV-Associated Oral Cancer

Reduced radiation for lymph node areas reduces side effects

Lung cancer illustration
September 29, 2026/Cancer/Radiation Oncology

Single-Fraction SBRT Shows Comparable Outcomes to Three-Fraction Approach in Early-Stage Lung Cancer

Large Cleveland Clinic analysis may help resolve a longstanding question over optimal fractionation

Ad